登录新浪财经APP 搜索【信披】查看更多考评等级 公司股东云南祥群投资有限公司及其一致行动人蓝波、深圳市畅思行实业发展有限公司、昆明南之图创 业投资合伙企业（有限合伙）、昆明云健宏创业投资合伙企业（有限合伙）、昆明春佳伟创业投资合伙 企业（有限合伙）、蓝抒悦、蓝心悦、者立纪、王宁、刘小涤、李梅、张燕飞、宋学金、吴丽敏，保证 向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ■ 健之佳医药连锁集团股份有限公司（以下简称"公司"）实际控制人之一蓝波先生100%控股的云南祥群 投资有限公司（以下简称"云南祥群"）计划自2026年1月1日起6个月内，通过上海证券交易所交易系统 以集中竞价交易方式增持公司A股股份，增持总金额5,000万元，资金来源为自有资金及股票增持专项贷 款。具体增持计划内容详见公司于2026年1月1日在上海证券交易网站披露的《关于实际控制人的一致行 动人以自有资金及专项贷款增持公司股份计划的公告》（公告编号：2026-001）。 公司收到云南祥群《关于增持健之佳股份权益变动触及1%刻度的告知 ...

Group 1 - The main subject of the increase is Yunnan Xiangqun Investment Co., Ltd., which is 100% controlled by Lan Bo, one of the actual controllers of the company, holding 13,818,299 shares, accounting for 8.9414% of the total share capital [2] - The increase plan involves Yunnan Xiangqun intending to increase its holdings of the company's A-shares by a total amount of 50 million yuan within six months through the Shanghai Stock Exchange trading system, using its own funds and a special loan for stock purchases [2] - The increase plan will not trigger a mandatory tender offer and will not lead to changes in the company's controlling shareholder or actual controller [2] Group 2 - The increase plan is in compliance with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Management Measures for the Acquisition of Listed Companies [5] - The increase behavior will not affect the company's listing status or lead to changes in the distribution of the company's equity that would jeopardize listing conditions [5] - The company will continuously monitor the situation regarding the increase of shares by the actual controller and its concerted actors, and will fulfill its information disclosure obligations in a timely manner [5]

Core Viewpoint - The stock price of Jianzhijia has experienced a decline of 10.20% year-to-date, with a recent drop of 2.03% on December 22, 2025, indicating potential challenges in the company's market performance [2][1]. Company Overview - Jianzhijia Pharmaceutical Chain Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on September 27, 2004. It was listed on December 1, 2020. The company specializes in the retail of health products, including pharmaceuticals, health foods, personal care items, and daily consumables [2]. - The revenue composition of Jianzhijia includes 72.60% from prescription and non-prescription drugs (with non-prescription drugs at 39.64% and prescription drugs at 32.96%), 7.44% from medical devices, and smaller percentages from other categories such as health foods and personal care products [2]. Financial Performance - For the period from January to September 2025, Jianzhijia reported a revenue of 6.549 billion yuan, a year-on-year decrease of 2.77%, and a net profit attributable to shareholders of 101 million yuan, down 0.22% year-on-year [2]. - The company has distributed a total of 715 million yuan in dividends since its A-share listing, with 473 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Jianzhijia had 15,100 shareholders, a slight decrease of 0.04% from the previous period, with an average of 10,240 circulating shares per shareholder, which increased by 0.04% [2]. - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B Fund holds 7.1 million shares, unchanged from the previous period, while the Guangfa Innovation Upgrade Mixed Fund has exited the top ten list [3].

Core Viewpoint - The stock price of Jianzhijia has experienced a decline of 10.24% year-to-date, with a recent slight recovery in the last five trading days, indicating potential volatility in the market performance of the company [2]. Group 1: Stock Performance - As of December 19, Jianzhijia's stock price decreased by 2.03%, trading at 19.76 yuan per share, with a total market capitalization of 30.54 billion yuan [1]. - The stock has shown a 2.60% increase over the last five trading days and a 0.51% increase over the last 20 days, while it has declined by 8.18% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Jianzhijia reported a revenue of 6.549 billion yuan, reflecting a year-on-year decrease of 2.77%, and a net profit attributable to shareholders of 101 million yuan, down by 0.22% year-on-year [2]. - The company has distributed a total of 715 million yuan in dividends since its A-share listing, with 473 million yuan distributed over the past three years [3]. Group 3: Business Overview - Jianzhijia, established on September 27, 2004, and listed on December 1, 2020, operates in the health product retail sector, offering a range of products including pharmaceuticals, health foods, personal care items, and daily consumables [2]. - The revenue composition of Jianzhijia includes 72.60% from prescription and non-prescription drugs, with non-prescription drugs accounting for 39.64% and prescription drugs for 32.96% [2]. - The company is categorized under the pharmaceutical and biological industry, specifically in the offline pharmacy segment, and is associated with concepts such as retail pharmacies and family doctor services [2].

Core Viewpoint - The legal opinion from Beijing DeHeng Law Offices confirms that the differentiated dividend distribution plan of Jianzhijia Pharmaceutical Chain Group Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [6]. Group 1: Reasons for Differentiated Dividend - Jianzhijia held its sixth board meeting on June 20, 2024, approving a share repurchase plan using self-owned funds to maintain company value and shareholder rights, with 1,143,260 shares repurchased by the announcement date [2]. - A subsequent board meeting on September 19, 2024, approved another share repurchase plan, resulting in an additional 903,400 shares repurchased [4]. - On October 29, 2024, a third board meeting approved a plan to repurchase 4,338,200 shares, totaling 6,384,860 shares that will not participate in profit distribution [4]. Group 2: Differentiated Dividend Plan - The company plans to distribute a cash dividend of RMB 11.00 per 10 shares (including tax) based on the total share capital minus the repurchased shares, resulting in a total of 162,973,874.80 RMB to be distributed [5]. - The total share capital as of the legal opinion date is 154,542,928 shares, with 6,384,860 shares excluded from the distribution, leading to 148,158,068 shares participating in the dividend [5]. Group 3: Calculation Basis for Differentiated Dividend - The reference price for ex-dividend is calculated as approximately 22.0500 RMB per share, based on the closing price of 23.15 RMB minus the cash dividend [5]. - The virtual distribution calculation shows a minor impact on the ex-dividend reference price, estimated at approximately 0.2059% [5]. Group 4: Conclusion - The legal opinion concludes that the differentiated dividend distribution plan is in accordance with the Company Law, Securities Law, and relevant regulations, ensuring no detriment to the company or its shareholders [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次上市流通的股票类型为非公开发行股份；股票认购方式为网下，上市股数为13,818,299股，占公 司总股本8.94%。 本次股票上市流通总数为13,818,299股。 ● 本次股票上市流通日期为2025年4月29日。 一、本次限售股上市类型 健之佳医药连锁集团股份有限公司（曾用名：云南健之佳健康连锁店股份有限公司，以下简称"公司"） 于2022年3月15日收到经中国证券监督管理委员会《关于核准云南健之佳健康连锁店股份有限公司非公 开发行股票的批复》(证监许可[2022]539号文)，核准向云南祥群投资有限公司（以下简称"云南祥群"） 非公开发行人民币普通股（A股）股票6,813,757股（以下简称"本次非公开发行股份"）。此后，2022- 2024年公司实施利润分配以资本公积转增股本，云南祥群上述持股数量变更为13,818,299股。 本次发行新增股份的登记托管手续于2022年4月29日在中国证券登记结算 ...

证券代码：605266 证券简称：健之佳 公告编号：2025-008 健之佳医药连锁集团股份有限公司 关于公司实际控制人股份提前解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 1、截止本公告日，健之佳医药连锁集团股份有限公司（以下简称"公司"） 实际控制人蓝波先生及其一致行动人合计持有公司股份 62,866,051 股，占公司 股份总数的 40.13%。本次解除质押后，累计质押股份 13,818,299 股，占其合计 持股总数的 21.98%,占公司总股本的 8.82%。 2、实际控制人蓝波先生直接持有公司 21,572,958 股股份，占公司股份 总数的 13.77%。本次解除质押后，其质押的股份已全部解除质押。 | 持股数量 | 21,572,958 股 | | --- | --- | | 持股比例 | 13.77% | | 剩余被质押股份数量 | 0 股 | | 剩余被质押股份数量占其所持股份比例 | 0.00% | | 剩余被质押股份数量占公司总股本比例 | 0.00% | 二、截至公告 ...